

**Tabled/Not Approved:**

- A. Biosimilars **TABLED**

**APPROVED:**

- B. Biofire Critical Values
- C. Epidural Analgesia (PCEA), Patient Management Nursing Policy
- D. Order Sets and Supporting Documents Advancing Directly to MEC (no med changes)
  - a. Neonatal Abstinence
  - b. ACTH and Supporting Policy
  - c. Infusion Center/CDU Anemia PRBC Transfusion
  - d. Transfusion orders for outpatients
  - e. TCH
  - f. mFOLFIRI +/- Avastin
  - g. mFOLFIRI +/- cetuximab
  - h. mFOLFOX6 +/- Avastin
  - i. PACLitaxel-trastuzumab Q21D
  - j. PACLitaxel-trastuzumab Weekly
  - k. TC (DOCEtaxel Cytoxan)
  - l. CI 5FU-leucovorin +/- Avastin
- E. Expedited Order Sets (received temporary approval for use before MEC vote)
  - a. Ampicillin Desensitization Orders
  - b. Ventilator Orders and Protocol
- F. Order Sets Advancing from P&T Committee
  - a. Enteral Nutrition Orders
- G. CRCL calculation to Meditech
- H. Oral chemo from home: MEC pre- approved that Oncology is to be consulted prior to chemo being given to patient. P&T will review and approve and it will then be brought back to MEC as INFORMATIONAL only.

**Pharmacy and Therapeutics Committee (S. Kharal)**

- A. Formulary: Addition of Breo Ellipta; Deletion of Advair
- B. Formulary: Deletion of Atrovent Inhaler
- C. Formulary: Automatic Substitution of Spiriva Respimat to Spirivira Handihaler
- D. Formulary: Addition of Osmolite 1.5
- E. Over-Ride Medication List
- F. Annual Formulary Review